05 June 2014 - Swedish Orphan Biovitrum AB (Sobi) will open its North American operations in Waltham, Massachusetts on 16 June 2014. Sobi worked closely with the Massachusetts Life Sciences Center as they developed their plans for their Massachusetts office. Sobi had originally set up its US affiliate in 2012 in Ardmore, Pennsylvania.
"We are strengthening our focus in the United States and Canada, and building our team in the Boston area will allow us to better address the needs of patients and healthcare providers in the region," said Geoffrey McDonough, CEO and President, Sobi.
"Thanks to our growth strategy of investing in education, innovation and infrastructure, Massachusetts continues to lead the world in life sciences," said Governor Deval Patrick.
"We are establishing our North American head office in Waltham as we recognize Massachusetts being one of the largest concentrations of biotech activity in the world. The region has established a broad-based biotech industry segment, and with Massachussetts as a major driver for global biotechnology innovation there is a strong talent pool here," said Rami Levin, Vice President North America, Sobi.
"On behalf of the Center, I would like to extend a warm welcome to the team at Sobi as they relocate their North American operations to Massachusetts," said Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center, the agency charged with implementing Governor Patrick's 10-year, $1 billion Life Sciences Initiative.
Sobi is an international specialty healthcare company dedicated to rare diseases. The product portfolio is primarily focused on Inflammation and Genetic diseases, with two late stage biological development projects within Haemophilia. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm.